Teva Pharmaceutical Industries Ltd. submitted an NDA for ecopipam to the FDA.
9 reports, 5 independent
Updated Aug 30
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 9
- Developments
- 2
- Repetition
- 78%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Teva Pharmaceutical Industries Ltd. submitted an NDA for ecopipam to the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA accepted NDA for ecopipam treatment.1 source
Teva submitted an NDA for ecopipam to the FDA.2 sources
Keep exploring
The entities involved
- FDA
-
Teva Pharmaceutical Industries Ltd.
Israeli pharmaceutical company
Related events
- Teva's acquired product is currently undergoing review by the FDA.
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- EMA validated marketing authorization and FDA accepted NDA for Pharvaris N.V.'s lead drug.
- Kowa's New Drug Application (NDA) for drug K-911 was accepted by the FDA for review.
- Iovance Biotherapeutics received FDA approval for its therapy, and the company is listed on Nasdaq.